(NYSE:VG) earned "Buy" rating by Dougherty & Company on Friday, August 4. This represents an increase of Infinity compared to the average daily volume of 0 call options. Moreover, Metropolitan Life Ins New York has 0.01% invested in Nektar Therapeutics (NASDAQ:NKTR) for 99,566 shares. It increased, as 14 investors sold Vonage Holdings Corp. shares while 65 reduced holdings. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The value of the position overall is up by 22.1%. The company's beta value is at 1.27. The disclosure for this sale can be found here. Breaking that down further, it has performed -63.38% for the week, -61.76% for the month, -64.86% over the last quarter, -80.60% for the past half-year and -88.60% for this a year ago. Finally, American International Group Inc. increased its stake in shares of Nektar Therapeutics by 5.8% during the 3rd quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company's stock valued at $1,582,000 after acquiring an additional 800 shares during the last quarter. Teachers Advisors LLC now owns 663,324 shares of the biopharmaceutical company's stock valued at $15,568,000 after acquiring an additional 337,868 shares during the last quarter. Louisiana State Employees Retirement System boosted its stake in Nektar Therapeutics by 0.8% in the 2nd quarter.
For the Current Quarter, the growth estimate for Nektar Therapeutics is -14.3%, while for the Next Quarter the stock growth estimate is 16.7%. Municipal Employees Retirement System of MI boosted its stake in shares of Nektar Therapeutics by 1.6% in the third quarter. Following the transaction, the senior vice president now directly owns 31,102 shares of the company's stock, valued at approximately $600,890.64.
Nektar Therapeutics (NASDAQ:NKTR) traded up $0.76 during midday trading on Monday, hitting $32.50. For NKTR, the company now has $37.97 Million of cash on the books, which is offset by $2.48 Million current liabilities.
Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings data on Tuesday, November 7th. Over the past month the firm's stock is 41.18%, 68.57% for the last quarter, 64.06% for the past six-months and 137.57% for the previous year. The business had revenue of $36.30 million for the quarter, compared to analysts' expectations of $32.42 million. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company's revenue for the quarter was up 321.2% on a year-over-year basis.
Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold.
Several other equities analysts have also recently issued reports on the company. On November 8 Jefferies Group LLC maintained a stock rating of "Buy" targeting a price of $35.00. Mizuho reissued a "buy" rating and issued a $30.00 target price on shares of Nektar Therapeutics in a report on Wednesday. Nektar Therapeutics (NDAQ:NKTR) has risen 41.52% since November 13, 2016 and is uptrending. As a result, Credit Suisse started Qudian off with an "outperform" rating and a price target of $33. $51,827 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Thomsen Jillian B. on Tuesday, May 16.
Rothschild Asset Management Inc says it bought 56,672 shares in the previous quarter increasing its exposure to Nektar Therapeutics by 5.0%. On November 7 analysts at Cowen and Company released a research note on NKTR setting a rating of "Outperform".
FedEx stock is up 0.5% to trade at $219.17, after Goldman Sachs initiated coverage on the delivery company with a "buy" rating and set its price target at $270 - a roughly 23% premium to current trading levels.
ILLEGAL ACTIVITY WARNING: This story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & worldwide trademark & copyright legislation.
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need.